Xcout Intel
DiogenX competitors & alternatives
The 12 closest competitors and alternatives to DiogenX among biotechnology companies — ranked by similarity to what DiogenX actually does, not by market-cap band.
Subscribe to see DiogenX’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About DiogenX
DiogenX is a preclinical-stage biotechnology company headquartered in Marseille, France, with research laboratories in Nice, dedicated to developing novel treatments for diabetes.
DiogenX at a glance
DiogenX is a biotechnology company headquartered in France. Its most recent funding round, Series A, raised $29.7M in May 2023. Xcout tracks 2 named people at DiogenX, including Benjamin Charles (CEO).
DiogenX leadership
- Benjamin CharlesCEO
- Eleanor L. RamosIndependent Member of its Board of Directors
DiogenX funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $29.7M | 6 named | |
| Seed | $4.9M | 7 named | |
| Seed | $4.9M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 DiogenX competitors
Ranked by semantic similarity — how close each company is to DiogenX by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Adocia is a clinical-stage biotechnology company that develops innovative formulations of proteins, peptides, and metabolic hormones. The company specializes in creating treatments for diabetes and obesity, as well as immunoprotective scaffolds for cell therapies.
Similar biotechnology company
AdipoPharma is a French biotech company dedicated to understanding the role of adipocyte cells in diabetes, focusing on lipid biosynthesis and whole-body metabolic health.
Similar biotechnology company
Paulex Bio Inc. is a biotechnology company headquartered in San Diego, California, focused on transformative treatments for type 1 and type 2 diabetes. Its lead approach targets beta cell regeneration through an oral administration.
Biotech
Vogenx, Inc. is a clinical-stage biopharmaceutical and life science company that discovers and develops novel therapeutics to treat metabolic and gastrointestinal diseases, including post-bariatric hypoglycemia and gastroparesis. Its lead drug candidate, mizagliflozin, is an oral small molecule designed to inhibit SGLT1, reducing glucose absorption and the secretion of insulin and gastric inhibitory peptide.
Similar biotechnology company
Atrogi is a clinical-stage biotechnology company headquartered in Stockholm, Sweden, pioneering the development of novel treatments for metabolic disorders.
Life Sciences (Therapeutics)
Eyegenex is a pharmaceutical manufacturing and drug discovery startup founded in 2023. The company is headquartered at Innovation Lane in La Jolla, San Diego, California.
Similar biotechnology company
Metabolic Solutions Development Company is a private biotechnology and drug discovery company founded in 2006. The firm focuses on investigating novel molecular targets and developing therapeutics to treat diabetes, metabolic syndrome, and related conditions.
Biotech
Endsulin, Inc. is a biotechnology company developing a liver-directed gene therapy for Type 1 Diabetes. Its proprietary technology aims to re-engineer liver cells to restore the body's natural ability to produce and regulate insulin, eliminating the need for artificial insulin delivery methods.
Similar biotechnology company
Regenacy Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts. The company focuses on developing breakthrough treatments for diabetic neuropathies and other debilitating conditions.
Similar biotechnology company
Inversago Pharma is a Canadian biotechnology company developing peripherally restricted CB1 receptor antagonists/inverse agonists for metabolic, fibrotic, and related diseases. Its drug-development programs are intended to serve patients with conditions such as obesity, metabolic syndrome, and diabetic kidney disease.
Similar biotechnology company
ProJenX, Inc. is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City. The firm focuses on neuroscience, developing novel, brain-penetrant therapies targeting biologically defined motor neuron diseases such as ALS. It advances research programs aimed at addressing severe neurodegenerative conditions.
Similar biotechnology company
Endogena Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Zürich, Switzerland, that discovers and develops first-in-class endogenous regenerative medicines to repair tissues.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of DiogenX and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for DiogenXand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →